Please assess the completion status of the following clinical trial:

Trial Title: Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age above 18 years.~2. Chronically infected with HCV genotype 4.~3. Treatment naïve.~4. No advanced fibrosis. Defined by the absence of clinical, radiological and laboratory signs of cirrhosis, and fibrosis assessment consistent with fibrosis stage (Metavir F2) or less by liver biopsy or transient elastography.~5. Not expected to leave the country for six months after the end of the intervention.~Exclusion Criteria:~1. Incapability of providing an informed consent to participate in the study.~2. Advanced fibrosis (Metavir F3) or cirrhosis (Metavir F4).~3. HIV or HBV co-infection~4. Organ transplant recipients.~5. Type 2 or 3 cryoglobulinemia with end-organ manifestations.~6. Proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis~7. Patients with a higher risk of transmitting the disease (Dialysis patients, incarcerated individuals, and intravenous drug abusers).~8. The use of any medication that has major interactions with Elbasvir or Grazoprevir as defined by the University of Liverpool drug interaction database, and cannot be discontinued or replaced with other alternatives.~9. Pregnancy.~10. History of hepatocellular carcinoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Elbasvir, Grazoprevir 50-100Mg Oral Tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).